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ACTH = adrenocorticotrophic hormone.
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The issue of whether to use corticosteroids for treating septic
shock has been ongoing for 20 or 30 years. Indeed, there is
much clinical and preclinical data that provide ample reasons
for using corticosteroids in septic shock. For instance, we
know that steroids increase catecholamine-stimulated
contractility, vasomotor catecholamine response, and
adrenergic receptor density. They also prevent desensitization
of β receptors, and they may provide adrenal replacement.
Cortisol status
The normal cortisol range is 5–24 µg/dl, and during the stress
response this rarely goes above 200 µg/dl. During septic
shock, classic adrenal insufficiency is rare (0–3% of cases)
and cortisol levels can range from 7 to 400 µg/dl. However,
50% of patients have levels below 20 µg/dl [1]. A series of
studies has examined the relative adrenal insufficiency that is
sometimes seen in septic shock. In one such study [2]
patients were stimulated with adrenocorticotrophic hormone
(ACTH) and their blood cortisol levels were measured at 0,
30, and 60 min. High mortality (82%) was associated with
high baseline cortisol levels that did not respond to ACTH
stimulation, whereas low mortality (26%) was associated with
low baseline cortisol levels that did respond to ACTH
stimulation. The intermediate values correlated with
intermediate mortality. This makes perfect sense and is very
logical, which is one of the reasons why I think it has been
adopted so quickly even though the data are fairly preliminary
and have not been reproduced.
A recent study examined a cohort of patients with septic
shock, separated them according to the presence or
absence of relative adrenal insufficiency, randomized them
into a placebo-controlled trial of steroid therapy, and then
stratified the analysis according to the adrenal insufficiency
variable [3]. At the onset, patients were tested for eligibility
using ACTH stimulation (although the results of this were not
immediately disclosed) and were then randomly assigned to
either hydrocortisone plus a fluorinated steroid or placebo for
7 days, in other words adrenal replacement therapy versus
none. The authors found that the group with relative adrenal
insufficiency (by the new criteria) were observed to have
statistically significantly improved survival. This tells us that
there is a select population of patients with adrenal
insufficiency during septic shock who improve when treated
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Abstract
Corticosteroid treatment of severe sepsis has been one of the most controversial clinical issues in
critical care.  In fact, few agents can claim to have been evaluated in scores of studies spanning 3–4
decades. Yet, convincing proof that corticosteroids are useful pharmacologic agents in the treatment
of this major clinical problem remains elusive. Recently, interest has resurfaced but this time the focus
is on a steroid replacement approach for what has now been termed “relative adrenal insufficiency”
rather than relying on the pharmacologic effects of steroids. This route holds promise, but proof
remains lacking.
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with steroids. In spite of the fact that the responders (to
ACTH) did not show a benefit, steroids worked in the group
as a whole. Hence, that categorization did not actually matter.
The ‘take home message’ ought to be that steroids work in
septic shock based on the overall study result in all enrolled
patients on an intent-to-treat basis. The sticky part is that this
population has been studied with steroids many times in the
past but without success.
Predicting outcome
So, do cortisol levels predict outcome? Several studies have
looked at this: five studies found that nonsurvivors have
higher levels of cortisol [4–8]; one found that survivors have
higher levels [9]; and three found no correlation [10–12].
Therefore, these reports taken together indicate that cortisol
levels do not predict outcome.
Does response to ACTH predict outcome? Two studies
[11,13] found no correlation with outcome, whereas two
other studies [10,14] found that a small (inadequate?)
response predicts death. Therefore, as yet there is not
enough evidence to state that response to ACTH is a
critically important determinant of outcome. Moreover, in
those studies, as well as in others, cortisol response is poorly
reproducible, even on the same day and in the same patient
[13,15]. Thus, even if response to ACTH were a good
measure, it is hard to get reliable clinical data.
So what do we truly know about cortisol assessment in the
intensive care unit? We know that appropriate levels are not
yet known, low random values are difficult to interpret, and
the concept of relative adrenal insufficiency is still poorly
established. Thus, why not study all comers in septic shock,
ignoring whether the patient is adrenally insufficient or not? A
couple of studies have addressed this.
A study by Briegel and colleagues [16] was a double-blind,
randomized trial of 40 patients that used the duration of
vasopressor therapy as the end-point. The inclusion criterion
was patients on vasopressor therapy with a cardiac index
greater than 4, in other words those with vasodilated shock.
The treatment was 100 mg hydrocortisone over the first
30 min, and then 0.18 mg/kg per hour for as long as the
vasopressor was required. For shock reversal there was no
significant difference from the control group; the median time
on vasopressor was different (but it is not clear what this
means because shock reversal showed no difference); and
the mortality was identical.
In another randomized double-blind study (this time in
41 patients with septic shock requiring vasopressors for
more than 48 hours) [17], the end-points were shock
reversal, haemodynamics, and survival. Hydrocortisone
100 mg was given every 8 hours for 5 days, versus placebo.
There was a statistically significant increase in the number of
patients whose shock had reversed by day 7, and there was
a trend toward increased survival, although the numbers
were small (6 deaths out of 22 in the corticosteroid group
and 13 out of 19 in the control group).
Based on those two studies [16,17], the ACTH response
does not appear to be necessary to see the shock effect.
One interpretation of these data would be that stress
steroids was the right approach, whereas high-dose pulse
steroid therapy in all patients (not just adrenal insufficient
patients) with septic shock was the wrong approach. Some
have stated that steroids might have worked if they had been
administered in a less potent way, for instance
100–300 mg/day over several days rather than the high
doses given in earlier studies, suggesting that replacement of
stress levels is what is important. However, this may not be
the case (see below).
Treating shock versus mortality
This brings us to the study conducted by Sprung and
colleagues of high-dose hydrocorticosteroids in septic shock
[18]. Here the end-points were survival and reversal of shock.
It was a randomized, prospective trial of 59 patients with
septic shock and systolic blood pressure below 90 mmHg
after adequate fluids. Treatment was industrial strength
methylprednisolone 30 mg/kg or dexamethasone 6 mg/kg,
and if shock persisted the dose was repeated after 4 hours
to a maximum of two doses (i.e. very short pulse therapy).
Shock reversal occurred more rapidly in the corticosteroid-
treated patients than in the control group, and this lasted until
day 14. There was no difference in mortality between the
control group and the corticosteroid group at 25 days.
Therefore, shock was actually improved more rapidly with
treatment but mortality was no different. There may have
been some late steroid deaths that were related to treatment.
What do we do now? One or two pulses of very high-dose
steroids is effective in reversing shock, but with a conflicting
effect on mortality. In summary, the pathophysiologic basis
for using steroids in septic shock remains very confusing; the
field is plagued by a large number of small trials and there is
no doubt that steroids carry risk. Thus, if we do not know that
something works, then we should not be using it. A large
randomized trial is really needed here to answer this
question. We do not know who to treat, we do not know
when to treat, we do not know the dose to use, and we
certainly do not know for how long to maintain treatment.
Finally, in a meta-analysis of all major studies conducted
since 1963 [19] it was shown that the relative risk for death
with corticosteroid treatment is slightly increased; in other
words, there is a slight increased risk for death associated
with corticosteroids. Therefore, the challenge is for us to
come up with a study design that can give us a clear idea of
what we should be doing in our everyday practice. For now,
the data indicate that we should not administer steroids to
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